PMID- 24272082
OWN - NLM
STAT- MEDLINE
DCOM- 20140609
LR  - 20211203
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 35
IP  - 4
DP  - 2014 Apr
TI  - Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and 
      its clinical significance.
PG  - 2975-81
LID - 10.1007/s13277-013-1382-y [doi]
AB  - This study aimed to analyze the expression, clinical significance of 
      proto-oncogene in non small cell lung cancer (NSCLC), and the biological effect 
      in its cell line by siRNA targeting wild-type p53-induced phosphatase 1 (Wip1). 
      Immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) 
      were, respectively, used to analyze Wip1 protein expression in 75 cases of NSCLC 
      and normal tissues to study the relationship between Wip1 expression and clinical 
      parameters. Wip1 siRNA was transiently transfected into papillary NSCLC H1299 
      cell by liposome-mediated method and was detected by RT-PCR and Western blot. MTT 
      assay, cell apoptosis, and cell cycle were also conducted as to the influence of 
      the downregulated expression of Wip1 that might be found on H1299 cells 
      biological effect. The positive rates of Wip1 protein was 69.3% in NSCLC tissues 
      but 16.0% expressed in normal tissues (P < 0.05). The relative content of Wip1 
      mRNA was 0.785 +/- 0.062 and 0.147 +/- 0.020 in NSCLC tissues and normal tissues, 
      respectively, with significant differences between the two types (P < 0.05). 
      There were no significant differences between Wip1 expression and sex, age, tumor 
      size, and pathological types (P > 0.05). However, there were significant 
      differences between Wip1 expression and lymph node metastasis, clinical stages, 
      and tumor differentiation (P < 0.05). Individuals with positive and negative 
      levels of Wip1 expression showed were statistically significant differences in 
      the 5-year overall survival rate (P < 0.05). RT-PCR and Western blot showed that 
      H1299 cell transfected Wip1 siRNA had a lower relative expressive content than 
      normal cell (P < 0.05). MTT assay, cell apoptosis, and cell cycles demonstrated 
      that H1299 cell transfected Wip1 siRNA had a lower survival fraction, higher cell 
      apoptosis, more percentage of the G0/G1 phases, and lower cells in the S phases 
      (P < 0.05). Wip1 protein and mRNA were increased in NSCLC, specifically in lymph 
      node metastasis, clinical stages, and tumor differentiation. Wip1 may be involved 
      in the biological processes of NSCLC cell proliferation, cell apoptosis, and cell 
      cycle.
FAU - Fu, Zhanzhao
AU  - Fu Z
AD  - Department of Tumor, The First Hospital of Qinhuangdao, No. 258, Wenhua Road, 
      Haigang District, Qinhuangdao, 066000, Hebei Province, China, sgg1980@tom.com.
FAU - Sun, Guogui
AU  - Sun G
FAU - Gu, Tao
AU  - Gu T
LA  - eng
PT  - Journal Article
DEP - 20131123
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - EC 3.1.3.16 (PPM1D protein, human)
RN  - EC 3.1.3.16 (Phosphoprotein Phosphatases)
RN  - EC 3.1.3.16 (Protein Phosphatase 2C)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/mortality/*pathology/therapy
MH  - Cell Proliferation
MH  - Female
MH  - Humans
MH  - Lung/chemistry
MH  - Lung Neoplasms/mortality/*pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Phosphoprotein Phosphatases/analysis/genetics/*physiology
MH  - Prognosis
MH  - Protein Phosphatase 2C
MH  - Proto-Oncogene Mas
EDAT- 2013/11/26 06:00
MHDA- 2014/06/10 06:00
CRDT- 2013/11/26 06:00
PHST- 2013/10/21 00:00 [received]
PHST- 2013/10/30 00:00 [accepted]
PHST- 2013/11/26 06:00 [entrez]
PHST- 2013/11/26 06:00 [pubmed]
PHST- 2014/06/10 06:00 [medline]
AID - 10.1007/s13277-013-1382-y [doi]
PST - ppublish
SO  - Tumour Biol. 2014 Apr;35(4):2975-81. doi: 10.1007/s13277-013-1382-y. Epub 2013 
      Nov 23.